CORENGAGER
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

CORENGAGER Trademark

Serial Number: 79418518 • Registration: 8190814

CORENGAGER is a trademark filed by Corregene Biotechnology Co., Ltd. on November 20, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Corregene Biotechnology Co., Ltd.

Room 317-2, 3rd Floor, Building 1,

Entity Type: 99

Trademark Details

Filing Date

November 20, 2024

Registration Date

March 31, 2026

Published for Opposition

February 10, 2026

Goods & Services

Protein in raw material form for scientific and medical research; diagnostic reagents, other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes; biochemical preparations for scientific purposes; biological preparations for use in cell cultures, other than for medical or veterinary purposes; chemical preparations for scientific purposes, other than for medical or veterinary use; diagnostic preparations for research laboratory use; biological preparations, for use in scientific research and development, other than for medical or veterinary purposes; biochemical reagents used for non-medical purposes; cell culture reagents for scientific or research purposes

Pharmaceutical preparations for detecting, analyzing, diagnosing and treating tumors, cancer, precancerous lesions, chronic infections, autoimmune diseases, fatty liver, inflammatory bowel disease, cervical neoplasia, viral infections, metabolic diseases, immunodeficiency, osteoarthritis, thyroid disease, glycometabolism disease, bone metabolic disease, gonad disease, kidney disease, cardiovascular disease, hepatic fibrosis, anemia, inflammation diseases, hepatitis disease, Epstein-Barr (EB) viruses, hormonal diseases, allergic, immune disorder, TORCH infections and immunoglobulin diseases; anti-cancer preparations; diagnostic preparations for medical or veterinary purposes; medicines for human purposes, namely, medicines for detecting, analyzing, diagnosing and treating tumors, cancer, precancerous lesions, chronic infections, autoimmune diseases, fatty liver, inflammatory bowel disease, cervical neoplasia, viral infections, metabolic diseases, immunodeficiency, osteoarthritis, thyroid disease, glycometabolism disease, bone metabolic disease, gonad disease, kidney disease, cardiovascular disease, hepatic fibrosis, anemia, inflammation diseases, hepatitis disease, Epstein-Barr (EB) viruses, hormonal diseases, allergic, immune disorder, TORCH infections and immunoglobulin diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; surgical implants comprised of living tissues; stem cells for medical purposes; vaccines; enzymes for medical purposes; biological preparations for medical purposes for the treatment of tumors, cancer, precancerous lesions, chronic infections, autoimmune diseases, fatty liver, inflammatory bowel disease, cervical neoplasia, viral infections, metabolic diseases, immunodeficiency, osteoarthritis, thyroid disease, glycometabolism disease, bone metabolic disease, gonad disease, kidney disease, cardiovascular disease, hepatic fibrosis, anemia, inflammation diseases, hepatitis disease, Epstein-Barr (EB) viruses, hormonal diseases, allergic diseases, immune disorder, TORCH infections and immunoglobulin diseases, infectious diseases, immune disease and fibrosis diseases

Chemical research; chemical analysis; chemical diagnosis for scientific or medical purposes in the nature of chemical analysis; development and testing of chemical production methods; chemical testing and chemistry consultation services; cosmetic research; bacteriological research; biological research; medical research; medical laboratory services, namely, for research, development, testing, and analysis purposes; clinical trials services for others, including the design, management, monitoring, data management, analysis, reporting, and regulatory compliance of clinical trials

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 31, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 31, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 4, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 16, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 8, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 8, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 8, 2026 TROA
REFUSAL PROCESSED BY IB
Aug 2, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 13, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jul 13, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 21, 2025 RFCR
NON-FINAL ACTION WRITTEN
May 20, 2025 CNRT
ASSIGNED TO EXAMINER
May 13, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 21, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 21, 2025 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 21, 2025 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 6, 2025 REPR